{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:26:48Z","timestamp":1779877608361,"version":"3.53.1"},"reference-count":108,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2019A1515011854"],"award-info":[{"award-number":["2019A1515011854"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["61427807"],"award-info":[{"award-number":["61427807"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2012I2004"],"award-info":[{"award-number":["2012I2004"]}]},{"name":"National Natural Science Foundation of China","award":["2019A1515011854"],"award-info":[{"award-number":["2019A1515011854"]}]},{"name":"National Natural Science Foundation of China","award":["61427807"],"award-info":[{"award-number":["61427807"]}]},{"name":"National Natural Science Foundation of China","award":["2012I2004"],"award-info":[{"award-number":["2012I2004"]}]},{"name":"Introduced Major Research and Development Project Funded by Fujian Province","award":["2019A1515011854"],"award-info":[{"award-number":["2019A1515011854"]}]},{"name":"Introduced Major Research and Development Project Funded by Fujian Province","award":["61427807"],"award-info":[{"award-number":["61427807"]}]},{"name":"Introduced Major Research and Development Project Funded by Fujian Province","award":["2012I2004"],"award-info":[{"award-number":["2012I2004"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T cells have been successfully used for hematological malignancies, especially for relapsed\/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphoma. Patients who have undergone conventional chemo-immunotherapy and have relapsed can achieve complete remission for several months with the infusion of CAR T-cells. However, side effects and short duration of response are still major barriers to further CAR T-cell therapy. To improve the efficacy, multiple targets, the discovery of new target antigens, and CAR T-cell optimization have been extensively studied. Nevertheless, the fact that the determination of the efficacy of CAR T-cell therapy is inseparable from the discussion of clinical application strategies has rarely been discussed. In this review, we will discuss some clinical application strategies, including lymphodepletion regimens, dosing strategies, combination treatment, and side effect management, which are closely related to augmenting and maximizing the efficacy of CAR T-cell therapy.<\/jats:p>","DOI":"10.3390\/cancers14184452","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T20:50:45Z","timestamp":1663188645000},"page":"4452","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies"],"prefix":"10.3390","volume":"14","author":[{"given":"Qianzhen","family":"Liu","sequence":"first","affiliation":[{"name":"School of Basic Medical Sciences, Guangdong Medical University, Dongguan 523000, China"},{"name":"Department of Pathology, The First People\u2019s Hospital of Foshan, Foshan 528000, China"},{"name":"Orthopaedic Center, Affiliated Hospital of Guangdong Medical University, Guangdong Medical University, Zhanjiang 524000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengping","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Guangdong Medical University, Dongguan 523000, China"},{"name":"Orthopaedic Center, Affiliated Hospital of Guangdong Medical University, Guangdong Medical University, Zhanjiang 524000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2048-0665","authenticated-orcid":false,"given":"Rongxue","family":"Wan","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Guangdong Medical University, Dongguan 523000, China"},{"name":"Orthopaedic Center, Affiliated Hospital of Guangdong Medical University, Guangdong Medical University, Zhanjiang 524000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Guangdong Medical University, Dongguan 523000, China"},{"name":"Orthopaedic Center, Affiliated Hospital of Guangdong Medical University, Guangdong Medical University, Zhanjiang 524000, China"},{"name":"Guangdong Engineering Research Center for Translation of Medical 3D Printing Application, Guangdong Provincial Key Laboratory of Medical Biomechanics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"609421","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory\/Recurrent Multiple Myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41417-018-0073-7","article-title":"Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma","volume":"26","author":"Bao","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-19-1339","article-title":"Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"26","author":"Heng","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-018-0572-x","article-title":"A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia","volume":"11","author":"Weng","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti\u2013PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","article-title":"Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT","volume":"7","author":"Wei","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/smim.1997.0091","article-title":"Restoration of T-cell homeostasis after T-cell depletion","volume":"9","author":"Mackall","year":"1997","journal-title":"Semin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: How lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI0215175","article-title":"T cell homeostatic proliferation elicits effective antitumor autoimmunity","volume":"110","author":"Dummer","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2014how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.coi.2005.02.002","article-title":"Less is more: Lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy","volume":"17","author":"Wrzesinski","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2020.00849","article-title":"CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences","volume":"10","author":"Vitale","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e013904","DOI":"10.1136\/bmjopen-2016-013904","article-title":"Third-generation CD28\/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: A non-randomised, open-label phase I trial protocol","volume":"6","author":"Tang","year":"2016","journal-title":"BMJ Open"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.15195","article-title":"Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB","volume":"181","author":"Li","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy","volume":"26","author":"Geyer","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e122627","DOI":"10.1172\/jci.insight.122627","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL","volume":"4","author":"Geyer","year":"2019","journal-title":"JCI Insight"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","article-title":"Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: A multi-center retrospective study","volume":"13","author":"Zhao","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated with High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e22510","DOI":"10.1097\/MD.0000000000022510","article-title":"Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report","volume":"99","author":"Liang","year":"2020","journal-title":"Medicine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1002\/ajh.25630","article-title":"Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome","volume":"94","author":"Tu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","article-title":"Simplified process for the production of anti\u2013CD19-CAR\u2013engineered T cells","volume":"15","author":"Tumaini","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-022-00688-4","article-title":"Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1078-0432.CCR-16-1125","article-title":"Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults with Acute Lymphoblastic Leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1016\/S2352-3026(20)30277-5","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: A systematic review and meta-analysis","volume":"7","author":"Anagnostou","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_61","first-page":"20","article-title":"A phase I study of CAR-T bridging HSCT in patients with acute CD19+ relapse\/refractory B-cell leukemia","volume":"20","author":"Ma","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"11471","DOI":"10.2147\/OTT.S277146","article-title":"Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant","volume":"13","author":"Li","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wen, S., Niu, Z., Xing, L., Wang, Y., Li, H., Kuang, N., Luo, J., Zhang, X., and Wang, F. (2018). CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: A case report. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5037-7"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clml.2020.04.007","article-title":"Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed\/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"20","author":"Hua","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41409-019-0650-x","article-title":"Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"55","author":"Boumendil","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/bmt.2010.209","article-title":"A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents","volume":"46","author":"Styczynski","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.16339","article-title":"Chimeric antigen receptor T-cell therapy as a bridge to haematopoietic stem cell transplantation for refractory\/relapsed B-cell acute lymphoblastic leukemia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e1115940","DOI":"10.1080\/2162402X.2015.1115940","article-title":"Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells","volume":"5","author":"Prukova","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated with CD19-Specific Chimeric Antigen Receptor\u2013Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1158\/1078-0432.CCR-17-1788","article-title":"Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice","volume":"24","author":"Gulati","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100695","DOI":"10.1016\/j.blre.2020.100695","article-title":"Revving the CAR\u2014Combination strategies to enhance CAR T cell effectiveness","volume":"45","author":"Bansal","year":"2021","journal-title":"Blood Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s10147-020-01699-6","article-title":"Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"25","author":"Goto","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","article-title":"Potent Anti-leukemia Activities of Chimeric Antigen Receptor\u2013Modified T Cells against CD19 in Chinese Patients with Relapsed\/Refractory Acute Lymphocytic Leukemia","volume":"23","author":"Hu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hon.2672","article-title":"Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor\u2013modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia","volume":"37","author":"Ma","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Chimeric Antigen Receptor T Cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty\u2013engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J. Immunother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.conctc.2018.01.006","article-title":"Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials","volume":"10","author":"Ananthakrishnan","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/19466315.2018.1462727","article-title":"An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials","volume":"10","author":"Chiuzan","year":"2018","journal-title":"Stat. Biopharm. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fimmu.2020.00147","article-title":"Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation","volume":"11","author":"Rovatti","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"Leblanc","year":"2004","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.18632\/oncotarget.24442","article-title":"IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner","volume":"9","author":"Loschinski","year":"2018","journal-title":"Oncotarget"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/2326-6066.CIR-15-0291","article-title":"Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells","volume":"4","author":"Browning","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.2147\/OTT.S198567","article-title":"Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma","volume":"12","author":"Li","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: Clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric Antigen Receptor T Cell\u2013Mediated Neurotoxicity in Nonhuman Primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wudhikarn, K., and Perales, M.-A. (2022). Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplant., 1\u201312.","DOI":"10.1038\/s41409-022-01756-w"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4452\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:31:00Z","timestamp":1760142660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":108,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14184452"],"URL":"https:\/\/doi.org\/10.3390\/cancers14184452","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]}}}